Name (Synonyms) | Correlation | |
---|---|---|
drug2211 | Self-Compassion for Chronic Pain Virtual Group Treatment Program Wiki | 0.71 |
drug1345 | Linagliptin Wiki | 0.71 |
drug1218 | Insulin regimen Wiki | 0.71 |
drug800 | Duvelisib Wiki | 0.71 |
drug2116 | Ruxolitinib Wiki | 0.24 |
drug1822 | Placebo Wiki | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
D059350 | Chronic Pain NIH | 0.29 |
D003924 | Diabetes Mellitus, Type 2 NIH | 0.29 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0005978 | Type II diabetes mellitus HPO | 0.29 |
HP:0012532 | Chronic pain HPO | 0.29 |
There are 2 clinical trials
The investigators hypothesize that JAK 1/2 inhibition with ruxolitinib, an FDA approved treatment for intermediate or high-risk myelofibrosis, could have a similar effect in patients with severe COVID-19, quelling the immune-hyperactivation, allowing for clearance of the virus and reversal of the disease manifestations.
Description: -Defined as increase in viral load of >0.5 log on two consecutive days, or >1 log increase in one day, not in keeping with any baseline trend of rising viral loads during the pre-treatment viral testing
Measure: Viral kinetics as measured by virologic failure Time: Through completion of follow-up (estimated to be 7 months)The exceedingly high mortality rates of severe and critical COVID-19 warrant the identification and evaluation of novel therapies that could potentially mitigate the advanced disease manifestations. Based on preclinical data from this institution and others, the investigators hypothesize that PI3K inhibition with duvelisib could potentially quell aberrant hyperactivtation of the innate immune system, preferentially polarize macrophages, reduce pulmonary inflammation, and limit viral persistence, thereby improving patient outcomes.
Description: -For those on a ventilator at the time of randomization
Measure: Duration of ventilator use Time: Through completion of follow-up (estimated to be 7 months)Description: -Defined as increase in viral load of >0.5 log on two consecutive days, or >1 log increase in one day, not in keeping with any baseline trend of rising viral loads during the pre-treatment viral testing
Measure: Viral kinetics as measured by virologic failure Time: Through completion of follow-up (estimated to be 7 months)